Deerfield Management’s Dyne Therapeutics DYN Stock Holding History

Deerfield Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-812,408	Closed	-$8.5M	–	139
2025 Q1	$8.5M	Buy	812,408 +376,755	+86%	+$5.39M	0.17%	72
2024 Q4	$10.3M	Hold	435,653	–	–	0.19%	65
2024 Q3	$15.6M	Buy	+435,653	New	+$17.3M	0.23%	57
2024 Q2	–	Sell	-7,940	Closed	-$225K	–	474
2024 Q1	$225K	Buy	+7,940	New	+$180K	﹤0.01%	314
2021 Q3	–	Sell	-787,000	Closed	-$16.6M	–	140
2021 Q2	$16.6M	Buy	787,000 +101,000	+15%	+$1.9M	0.29%	90
2021 Q1	$10.7M	Buy	686,000 +116,000	+20%	+$2.24M	0.22%	98
2020 Q4	$12M	Buy	570,000 +158,733	+39%	+$3.14M	0.24%	94
2020 Q3	$8.3M	Buy	+411,267	New	+$9.03M	0.2%	88

Other funds holding DYN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management's DYN Position: Q2 2025 in Review

Deerfield Management sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 812,408 shares — an estimated $8.5M sold.

Deerfield Management first reported a position in DYN in Q3 2020 and held it in 8 quarters. The position peaked at $16.6M in Q2 2021. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

Deerfield Management reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
Deerfield Management sold 812,408 Dyne Therapeutics shares in Q2 2025, an estimated $8.5M.
Deerfield Management first reported a position in Dyne Therapeutics in Q3 2020 and held it in 8 quarters.
Deerfield Management's Dyne Therapeutics position peaked at $16.6M in Q2 2021.
197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Deerfield Management's 13F filing for Q2 2025, filed 14 Aug 2025.